Bristol-Myers Squibb's stock is set to rise with FDA approvals, acquisitions, and a strong oncology portfolio, despite ...

Bicara Therapeutics, a clinical-stage biopharmaceutical company, focuses on brining transformative bifunctional therapies for ...

Bob Duggan’s success shows you don’t need a Ph.D., or even a college education, to make money in the complex world of biotech ...

A U.S. appeals court revived a lawsuit on Friday by healthcare and drug industry groups challenging the first-ever U.S. law ...

The FDA issued draft guidance on oncology clinical trials, taking the first steps toward formalizing a position that it's ...

(Yicai) Sept. 13 -- China’s five-year business outlook looks mixed to US firms operating in the country, as some industries ...

What’s next for Akeso and Summit Therapeutics after their cancer immunotherapy outperformed Merck’s Keytruda in a large Phase 3 clinical trial? Who’s the iconoclastic outsider behind Summit ...

These apps are a breath of fresh air in a world filled with in-app purchases and recurring subscriptions. These are some of my favorite free iPhone apps currently on the market. It turns out that ...

Merck’s cancer immunotherapy Keytruda is the drug industry’s biggest blockbuster, bringing in $25 billion in sales last year. For years drug companies have sought to beat the therapy to no avail.

(RTTNews) - Merck & Co., Inc. (MRK) and Daiichi Sankyo (DSKYF.PK) announced that an interim analysis of the dose-optimization phase of the ongoing IDeate-Lung01 Phase 2 trial shows ifinatamab ...

Merck (MRK) and Daiichi Sankyo (DSNKY) announce early results from a Phase 2 trial of lung cancer drug I-DXd, an antibody ...

We note that Merck & Co., Inc. (NYSE:MRK) does have debt on its balance sheet. But the real question is whether this debt is making the company risky. Debt assists a business until the business ...